Table 1 Demographic and clinicopathologic characteristics of advanced-stage CHL patients
Variable | Advanced-stage CHL | |
|---|---|---|
Low IPS N = 20 | High IPS N = 20 | |
Age (years, mean ± SD) | 32.55 ± 14.13 | 30.80 ± 13.63 |
Sex, n (%) | ||
Male | 9 (45%) | 12 (60%) |
Female | 11 (55%) | 8 (40%) |
Subtype, n (%) | ||
Nodular sclerosis | 13 (65%) | 12 (60%) |
Mixed cellularity | 5 (25%) | 6 (30%) |
Lymphocyte depleted | 1 (5%) | 2 (10%) |
Lymphocyte rich | 1 (5%) | 0 |
Haemoglobin (g/dl, median (min–max)) | 11.6 (2.7–14.1) | 9.5 (7.4–14.6) |
Leukocyte (/µL, mean ± SD) | 11.216 ± 5320.96 | 21.659.8 ± 15.310.17 |
Lymphocyte (%, median (min–max)) | 13.5 (6.1–41.4) | 4.3 (1.3–12.2) |
Albumin (g/dl, mean ± SD) | 3.67 ± 0.53 | 2.75 ± 0.52 |
Stage, n (%) | ||
2 | 3 (15%) | 0 |
3 | 8 (40%) | 4 (20%) |
4 | 9 (45%) | 16 (80%) |